Research progress of tissue plasminogen activator in ophthalmic treatment_Chinese Journal of Ocular Fundus Diseases

Authors：

Tan Huang , Zhang Hui ,  Li Xiaorong

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, China;

Corresponding author：

Li Xiaorong, Email: xiaorli@163.com

Keywords：

Tissue plasminogen activator; Subretinal Hemorrhage; subretinal hemorrhage; Central retinal artery occlusion; Review

DOI：

10.3760/cma.j.cn511434-20250120-00032

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Tissue plasminogen activator (t-PA), a serine protease capable of promoting fibrin degradation and thrombus dissolution, plays a pivotal role in the management of cardiovascular and cerebrovascular diseases. In recent years, its ophthalmic applications have expanded significantly. Intravitreal administration of t-PA demonstrates efficacy in inducing posterior vitreous detachment, thereby enhancing surgical success rates. Combined application with vitrectomy markedly improves outcomes in subretinal hemorrhage management. Systemic thrombolysis via intravenous or intra-arterial routes effectively alleviates central retinal artery occlusion, while suprachoroidal injection facilitates resolution of suprachoroidal hemorrhage. Notably, the synergistic effect of subretinal co-administration with anti-vascular endothelial growth factor agents enhances anti-angiogenic efficacy, offering novel therapeutic strategies for ocular neovascular disorders. In the future, it is necessary to further clarify the best indication of t-PA, improve the treatment scheme, and explore the combined application with other treatment methods to promote the innovation of ophthalmic treatment.

1.	Feske SK. Ischemic Stroke[J]. Am J Med, 2021, 134(12): 1457-1464. DOI: 10.1016/j.amjmed.2021.07.027.
2.	Warach SJ, Dula AN, Milling TJ Jr. Tenecteplase thrombolysis for acute ischemic stroke[J]. Stroke, 2020, 51(11): 3440-3451. DOI: 10.1161/STROKEAHA.120.029749.
3.	Levin EG, Santell L. Santell, stimulation and desensitization of tissue plasminogen activator release from human endothelial cells[J]. J Biol Chem, 1988, 263(19): 9360-9365. DOI: 10.1016/S0021-9258(19)76549-1.
4.	Geppert A, Graf S, Beckmann R, et al. Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease[J]. Arterioscler Thromb Vasc Biol, 1998, 18(10): 1634-1642. DOI: 10.1161/01.atv.18.10.1634.
5.	Levin EG, Marotti KR, Santell L. Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells. Dependence on the elevation of messenger RNA[J]. J Biol Chem, 1989, 264(27): 16030-16036. DOI: 10.1016/S0021-9258(18)71583-4.
6.	Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans[J]. Arterioscler Thromb Vasc Biol, 2005, 25(12): 2470-2479. DOI: 10.1161/01.ATV.0000189309.05924.88.
7.	Bellien J, Iacob M, Richard V, et al. Evidence for wall shear stress-dependent t-PA release in human conduit arteries: role of endothelial factors and impact of high blood pressure[J]. Hypertens Res, 2021, 44(3): 310-317. DOI: 10.1038/s41440-020-00554-5.
8.	Rijken DC. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects[J]. Baillieres Clin Haematol, 1995, 8(2): 291-312. DOI: 10.1016/s0950-3536(05)80269-0.
9.	何香莲. 增殖性糖尿病视网膜病变血浆和眼内组织VEGF与t-PA及PAI的表达及其相关性研究[D]. 银川: 宁夏医科大学, 2014.He XL. Expression and correlation of VEGF, t-PA and PAI in plasma and intraocular tissue of proliferative diabetic retinopathy [D]. Yinchuan: Ningxia Medical University, 2014.
10.	Parmer RJ, Gong Y, Yoo SH, et al. Neuroendocrine targeting of tissue plasminogen activator (t-PA)[J/OL]. J Neurol Disord Stroke, 2020, 7(1): 1153[2020-02-12]. https://pubmed.ncbi.nlm.nih.gov/32549050/.
11.	郑斯莉, 缪朝玉. 组织型纤溶酶原激活剂治疗急性缺血性脑卒中的作用机制及临床应用[J]. 中国药理学与毒理学杂志, 2018, 32(8): 595-606. DOI: 10.3867/j.issn.1000-3002.2018.08.002.Zheng SL, Miao CY. Mechanism and clinical application of tissue-type plasminogen activator in treatment of acute ischemic stroke[J]. Chin J Pharmacol Toxicol, 2018, 32(8): 595-606. DOI: 10.3867/j.issn.1000-3002.2018.08.002.
12.	Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review[J]. JAMA, 2022, 327(7): 662-675. DOI: 10.1001/jama.2022.0358.
13.	Hilkens NA, Casolla B, Leung TW, et al. Stroke[J]. Lancet, 2024, 403(10446): 2820-2836. DOI: 10.1016/s0140-6736(24)00642-1.
14.	Babu N, Kumar J, Kohli P, et al. Perfluoro-n-octane-assisted mega Weiss-ring technique for posterior vitreous detachment induction in retinal detachment[J]. Indian J Ophthalmol, 2019, 67(9): 1463-1465. DOI: 10.4103/ijo.IJO_2068_18.
15.	Shiraki A, Shiraki N, Sakimoto S, et al. Intraoperative challenges and management of fibrovascular membrane with tractional retinoschisis in proliferative diabetic retinopathy[J]. BMC Ophthalmol, 2024, 24(1): 299. DOI: 10.1186/s12886-024-03555-x.
16.	Hsu AY, Chen SN. Ultrawide-field optical coherence tomography in transvitreal and subretinal fibrinoid syndrome: a case report[J]. Case Rep Ophthalmol, 2023, 14(1): 147-152. DOI: 10.1159/000529912.
17.	Tandias R, Lemire CA, Palvadi K, et al. Posterior vitreous detachment status as a predictive factor for outcomes of vitrectomy for diabetic vitreous hemorrhage[J]. Retina, 2022, 42(6). DOI: 10.1097/IAE.0000000000003453.
18.	Bu SC, Kuijer R, Van Der Worp RJ, et al. The ultrastructural localization of type II, IV, and VI collagens at the vitreoretinal interface[J/OL]. PLoS One, 2015, 10(7): e0134325[2015-07-31]. https://pubmed.ncbi.nlm.nih.gov/26230410/. DOI: 10.1371/journal.pone.0134325.
19.	Phillips JD, Hwang ES, Morgan DJ, et al. Structure and mechanics of the vitreoretinal interface[J/OL]. J Mech Behav Biomed Mater, 2022, 134: 105399[2022-08-05]. https://pubmed.ncbi.nlm.nih.gov/35963021/. DOI: 10.1016/j.jmbbm.2022.105399.
20.	Lee YS, Wang NK, Chen YP, et al. Plasmin enzyme-assisted vitrectomy in pediatric patients with vitreoretinal diseases[J]. Ophthalmic Res, 2016, 56(4): 193-201. DOI: 10.1159/000447406.
21.	Maleki A, Tohidi-Zand SR, Amirizadeh N, et al. Intravitreal autologous plasmin prepared by urokinase for vitreolysis: a pilot study[J]. Eur J Ophthalmol, 2016, 26(1): 67-70. DOI: 10.5301/ejo.5000628.
22.	Grinton M, Steel DH. Cochrane corner: ocriplasmin-why isn't it being used more?[J]. Eye (Lond), 2019, 33(8): 1195-1197. DOI: 10.1038/s41433-019-0407-1.
23.	Aras C, Senturk F, Koytak A, et al. In vivo generated autologous plasmin assisted vitrectomy in young patients[J]. Int J Retina Vitreous, 2022, 8(1): 36. DOI: 10.1186/s40942-022-00391-3.
24.	冯斐, 赵培泉. 外伤性出血性视网膜脱离的手术疗效分析[J]. 眼外伤职业眼病杂志, 2007, 29(5): 358-360. DOI: 10.3760/cma.j.issn.2095-1477.2007.05.014.Feng F, Zhao PQ. Clinical effect of hemorrhagic retinal detachment due to trauma[J]. Chin J Ocul Traum Occupat Eye Dis, 2007, 29(5): 358-360. DOI: 10.3760/cma.j.issn.2095-1477.2007.05.014.
25.	Le Mer Y, Korobelnik JF, Morel C, et al. TPA-assisted vitrectomy for proliferative diabetic retinopathy: results of a double-masked, multicenter trial[J]. Retina, 1999, 19(5): 378-382. DOI: 10.1097/00006982-199909000-00002.
26.	Hesse L, Kroll P. TPA-assisted vitrectomy for proliferative diabetic retinopathy[J]. Retina, 2000, 20(3): 317-318. DOI: 10.1097/00006982-200003000-00021.
27.	Hesse L, Chofflet J, Kroll P. Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy[J]. Ger J Ophthalmol, 1995, 4(6): 323-327.
28.	Chuang CC, Chen SN. Induction of posterior vitreous detachment in pediatric vitrectomy by preoperative intravitreal injection of tissue plasminogen activator[J]. J Pediatr Ophthalmol Strabismus, 2016, 53(2): 113-118. DOI: 10.3928/01913913-20160209-01.
29.	Aoki R, Hatano M, Higashijima F, et al. Intravitreal tissue plasminogen activator injection for treatment-resistant diabetic macular edema of the vitrectomized eye[J]. Case Rep Ophthalmol, 2021, 12(3): 841-847. DOI: 10.1159/000518289.
30.	Liu RZ, Hu YJ, Wang TF, et al. A novel recombinant human microplasminogen induced complete posterior vitreous detachment without morphological change of retina in juvenile rabbits[J/OL]. Exp Eye Res, 2023, 230: 109465[2023-04-06]. https://pubmed.ncbi.nlm.nih.gov/37030582/. DOI: 10.1016/j.exer.2023.109465.
31.	Ghasemi Falavarjani K, Anvari P, Dehghan Niri M, et al. The effect of intravitreal recombinant tissue plasminogen activator injection on diabetic tractional fibrovascular membranes: Proposed criteria using optical coherence tomography[J]. Eur J Ophthalmol, 2021, 32(1): 424-428. DOI: 10.1177/1120672121998224.
32.	Raczyńska D, Lipowski P, Zorena K, et al. Enzymatic vitreolysis with recombinant tissue plasminogen activator for vitreomacular traction[J]. Drug Des Devel Ther, 2015, 9: 6259-6268. DOI: 10.2147/dddt.S88361.
33.	Aras C, Senturk F, Erdur SK, et al. Invivo generated autologous plasmin enzyme assisted vitrectomy, partial circumferential-oral retinotomy, silicone oil injection in patients with chronic retinal detachment without posterior vitreous detachment[J]. Graefe's Arch Clin Exp Ophthalmol, 2024, 262(10): 3109-3116. DOI: 10.1007/s00417-024-06466-1.
34.	Casini G, Loiudice P, Menchini M, et al. Traumatic submacular hemorrhage: available treatment options and synthesis of the literature[J/OL]. Int J Retina Vitreous, 2019, 5: 48[2019-12-11]. https://pubmed.ncbi.nlm.nih.gov/31890278/. DOI: 10.1186/s40942-019-0200-0.
35.	Hattenbach LO, Grisanti S, Feltgen N, et al. Management of submacular hemorrhage : what, when, how?[J]. Ophthalmologe, 2020, 117(9): 848-857. DOI: 10.1007/s00347-020-01192-5.
36.	Chang W, Garg SJ, Maturi R, et al. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration[J]. Am J Ophthalmol, 2014, 157(6): 1250-1257. DOI: 10.1016/j.ajo.2014.02.007.
37.	Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits[J]. Am J Ophthalmol, 1982, 94(6): 762-773. DOI: 10.1016/0002-9394(82)90301-4.
38.	Imam MU, Zhang S, Ma J, et al. Antioxidants mediate both iron homeostasis and oxidative stress[J/OL]. Nutrients, 2017, 9(7): 671[2017-06-28]. https://pubmed.ncbi.nlm.nih.gov/28657578/. DOI: 10.3390/nu9070671.
39.	Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage[J]. Surv Ophthalmol, 1997, 42(3): 195-213. DOI: 10.1016/s0039-6257(97)00089-1.
40.	Gok M, Karabaş VL, Aslan MS, et al. Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degeneration[J]. Indian J Ophthalmol, 2017, 65(6): 482-487. DOI: 10.4103/ijo.IJO_129_16.
41.	Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage[J]. Am J Ophthalmol, 1994, 118(5): 559-568. DOI: 10.1016/S0002-9394(14)76571-7.
42.	Rickmann A, Paez LR, Della Volpe Waizel M, et al. Functional and structural outcome after vitrectomy combined with subretinal rtPA Injection with or without additional intravitreal Bevacizumab injection for submacular hemorrhages[J/OL]. PLoS One, 2021, 16(4): e0250587[2021-04-30]. https://pubmed.ncbi.nlm.nih.gov/33930041/. DOI: 10.1371/journal.pone.0250587.
43.	Tiosano A, Gal-Or O, Fradkin M, et al. Visual acuity outcome in patients with subretinal hemorrhage - office procedure vs. surgical treatment[J]. Eur J Ophthalmol, 2022, 33(1): 506-513. DOI: 10.1177/11206721221098208.
44.	薛晓阳, 刘勃实, 李筱荣. 玻璃体切割术联合视网膜下注射组织型纤溶酶原激活剂对黄斑下出血的疗效观察[J]. 中华实验眼科杂志, 2024, 42(5): 448-452. DOI: 10.3760/cma.j.cn115989-20231012-00125.Xue XY, Liu BS, Li XR. Efficacy of vitrectomy combined with subretinal injection of tissue plasminogen activator on macular hemorrhage[J]. Chin J Exp Ophthalmol, 2024, 42(5): 448-452. DOI: 10.3760/cma.j.cn115989-20231012-00125.
45.	Wu TT, Kung YH, Hong MC. Vitreous hemorrhage complicating intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage[J]. Retina, 2011, 31(10): 2071-2077. DOI: 10.1097/IAE.0b013e31822528c8.
46.	Kitagawa Y, Shimada H, Mori R, et al. One-year outcome of intravitreal tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage in polypoidal choroidal vasculopathy[J/OL]. J Clin Med, 2022, 11(8): 2175[2022-04-13]. https://pubmed.ncbi.nlm.nih.gov/35456268/. DOI: 10.3390/jcm11082175.
47.	Pierre M, Mainguy A, Chatziralli I, et al. Macular hemorrhage due to age-related macular degeneration or retinal arterial macroaneurysm: predictive factors of surgical outcome[J/OL]. J Clin Med, 2021, 10(24): 5787[2021-12-10]. https://pubmed.ncbi.nlm.nih.gov/34945083/. DOI: 10.3390/jcm10245787.
48.	Stanescu-Segall D, Balta F, Jackson TL. Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature[J]. Surv Ophthalmol, 2016, 61(1): 18-32. DOI: 10.1016/j.survophthal.2015.04.004.
49.	Guthoff R, Guthoff T, Meigen T, et al. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration[J]. Retina, 2011, 31(1): 36-40. DOI: 10.1097/IAE.0b013e3181e37884.
50.	Ogata M, Oh H, Nakata A, et al. Displacement of submacular hemorrhage secondary to age-related macular degeneration with subretinal injection of air and tissue plasminogen activator[J/OL]. Sci Rep, 2022, 12(1): 22139[2022-12-22]. https://pubmed.ncbi.nlm.nih.gov/36550175/. DOI: 10.1038/s41598-022-26289-6.
51.	Avcı R, Mavi Yıldız A, Çınar E, et al. Subretinal coapplication of tissue plasminogen activator and bevacizumab with concurrent pneumatic displacement for submacular hemorrhages secondary to neovascular age-related macular degeneration[J]. Turk J Ophthalmol, 2021, 51(1): 38-44. DOI: 10.4274/tjo.galenos.2020.72540.
52.	Iglicki M, Khoury M, Melamud JI, et al. Naïve subretinal haemorrhage due to neovascular age-related macular degeneration. pneumatic displacement, subretinal air, and tissue plasminogen activator: subretinal vs intravitreal aflibercept-the native study[J]. Eye (Lond), 2023, 37(8): 1659-1664. DOI: 10.1038/s41433-022-02222-z.
53.	Ong J, Zarnegar A, Corradetti G, et al. Advances in optical coherence tomography imaging technology and techniques for choroidal and retinal disorders[J/OL]. J Clin Med, 2022, 11(17): 5139[2022-08-31]. https://pubmed.ncbi.nlm.nih.gov/36079077/. DOI: 10.3390/jcm11175139.
54.	Zhao X, Zhao Q, Wang E, et al. Three-dimensional heads-up system assisted pars plana vitrectomy and subretinal recombinant tissue plasminogen activator injection for submacular hemorrhage[J]. Eye Vis (Lond), 2023, 10(1): 8. DOI: 10.1186/s40662-023-00326-5.
55.	Barzelay A, Daniels A, Cohen GY, et al. Pneumatic displacement with intravitreal tPA injection versus vitrectomy with sub retinal tPA injection in small and medium sub macular hemorrhages- a multicenter comparative study[J]. BMC Ophthalmol, 2024, 24(1): 218. DOI: 10.1186/s12886-024-03468-9.
56.	Ali Said Y, Dewilde E, Stalmans P. Visual outcome after vitrectomy with subretinal tpa injection to treat submacular hemorrhage secondary to age-related macular degeneration or macroaneurysm[J/OL]. J Ophthalmol, 2021, 2021: 3160963[2021-12-30]. https://pubmed.ncbi.nlm.nih.gov/35003789/. DOI: 10.1155/2021/3160963.
57.	Mehta N, Marco RD, Goldhardt R, et al. Central retinal artery occlusion: acute management and treatment[J]. Curr Ophthalmol Rep, 2017, 5(2): 149-159. DOI: 10.1007/s40135-017-0135-2.
58.	Yao Y, Song Q, Zhang J, et al. Retina-brain homology: the correlation between ophthalmic or retinal artery occlusion and ischemic stroke[J]. Eye Brain, 2024, 16: 25-38. DOI: 10.2147/EB.S454977.
59.	Bénard-Séguin É, Nahab F, Pendley AM, et al. Eye stroke protocol in in the emergency department[J/OL]. J Stroke Cerebrovasc Dis, 2024, 33(9): 107895[2024-07-28]. https://pubmed.ncbi.nlm.nih.gov/39079617/. DOI: 10.1016/j.jstrokecerebrovasdis.2024.107895.
60.	Venkatesh R, Joshi A, Maltsev D, et al. Update on central retinal artery occlusion[J]. Indian J Ophthalmol, 2024, 72(7): 945-955. DOI: 10.4103/ijo.Ijo_2826_23.
61.	Schorr EM, Rossi KC, Stein LK, et al. Characteristics and outcomes of retinal artery occlusion: nationally representative data[J]. Stroke, 2020, 51(3): 800-807. DOI: 10.1161/strokeaha.119.027034.
62.	Youn TS, Lavin P, Patrylo M, et al. Current treatment of central retinal artery occlusion: a national survey[J]. J Neurol, 2018, 265(2): 330-335. DOI: 10.1007/s00415-017-8702-x.
63.	Mac Grory B, Schrag M, Biousse V, et al. Management of central retinal artery occlusion: a scientific statement from the american heart association[J/OL]. Stroke, 2021, 52(6): e282-e294[2021-04-08]. https://pubmed.ncbi.nlm.nih.gov/33677974/. DOI: 10.1161/STR.0000000000000366.
64.	Kattah JC, Wang DZ, Reddy C. Intravenous recombinant tissue-type plasminogen activator thrombolysis in treatment of central retinal artery occlusion[J]. Arch Ophthalmol, 2002, 120(9): 1234-1236. DOI: 10.1001/archopht.120.9.1234.
65.	Schrag M, Youn T, Schindler J, et al. Intravenous fibrinolytic therapy in central retinal artery occlusion: a patient-level meta-analysis[J]. JAMA Neurol, 2015, 72(10): 1148-1154. DOI: 10.1001/jamaneurol.2015.1578.
66.	Liu Y, Cao S, Zhao Y, et al. Network meta-analysis of different thrombolytic strategies for the treatment of central retinal artery occlusion[J]. Semin Ophthalmol, 2024, 39(2): 129-138. DOI: 10.1080/08820538.2023.2249539.
67.	Shahjouei S, Bavarsad Shahripour R, Dumitrascu OM. Thrombolysis for central retinal artery occlusion: an individual participant-level meta-analysis[J]. Int J Stroke, 2024, 19(1): 29-39. DOI: 10.1177/17474930231189352.
68.	Raber FP, Gmeiner F, Dreyhaupt J, et al. Thrombolysis in central retinal artery occlusion: a retrospective observational study[J]. J Neurol, 2022, 270: 891-897. DOI: 10.1007/s00415-022-11439-7.
69.	Kožner P, Eichenmann L, Ceska Burdova M, et al. Long-term outcomes of intravenous fibrinolysis in central retinal artery occlusion[J/OL]. Sci Rep, 2023, 13(1): 20505[2023-11-22]. https://pubmed.ncbi.nlm.nih.gov/37993533/. DOI: 10.1038/s41598-023-47987-9.
70.	Lin J C, Song S, Ng SM, et al. Interventions for acute non-arteritic central retinal artery occlusion[J/OL]. Cochrane Database Syst Rev, 2023, 1(1): Cd001989[2023-01-30]. https://pubmed.ncbi.nlm.nih.gov/36715340/. DOI: 10.1002/14651858.CD001989.pub3.
71.	Tiwari V, Bagga SSJ, Prasad R, et al. A review of current literature on central retinal artery occlusion: its pathogenesis, clinical management, and treatment[J/OL]. Cureus, 2024, 16(3): e55814[2024-03-08]. https://pubmed.ncbi.nlm.nih.gov/38590501/. DOI: 10.7759/cureus.55814.
72.	Smith MJ, Benson MD, Tennant M, et al. Central retinal artery occlusion: a retrospective study of disease presentation, treatment, and outcomes[J]. Can J Ophthalmol, 2023, 58(4): 318-323. DOI: 10.1016/j.jcjo.2022.02.015.
73.	Cantor LB, Katz LJ, Spaeth GL. Complications of surgery in glaucoma. suprachoroidal expulsive hemorrhage in glaucoma patients undergoing intraocular surgery[J]. Ophthalmology, 1985, 92(9): 1266-1270. DOI: 10.1016/s0161-6420(85)33872-1.
74.	Taylor DM. Expulsive hemorrhage[J]. Am J Ophthalmol, 1974, 78(6): 961-966. DOI: 10.1016/0002-9394(74)90809-5.
75.	Stein JD, Zacks DN, Grossman D, et al. Adverse events after pars plana vitrectomy among medicare beneficiaries[J]. Arch Ophthalmol, 2009, 127(12): 1656-1663. DOI: 10.1001/archophthalmol.2009.300.
76.	黄易, 胡海坚, 张旭. 暴发性脉络膜上腔出血的研究进展[J]. 国际眼科纵览, 2022, 46(6): 522-527. DOI: 10.3760/cma.j.issn.1673-5803.2022.06.009.Huang Y, Hu HJ, Zhang X. Advance in the study of expulsive suprachoroidal hemorrhage[J]. Int Rev Ophthalmol, 2022, 46(6): 522-527. DOI: 10.3760/cma.j.issn.1673-5803.2022.06.009.
77.	Kunjukunju N, Gonzales CR, Rodden WS. Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage[J]. Clin Ophthalmol, 2011, 5: 155-157. DOI: 10.2147/opth.S16134.
78.	Fei P, Jin HY, Zhang Q, et al. Tissue plasminogen activator-assisted vitrectomy in the early treatment of acute massive suprachoroidal hemorrhage complicating cataract surgery[J]. Int J Ophthalmol, 2018, 11(1): 170-171. DOI: 10.18240/ijo.2018.01.27.
79.	Osaadon P, Belfair N, Lavy I, et al. Intracameral r-tPA for the management of severe fibrinous reactions in tass after cataract surgery[J]. Eur J Ophthalmol, 2022, 32(1): 200-204. DOI: 10.1177/11206721211002064.
80.	Yoshino H, Seki M, Ueda J, et al. Fibrin membrane pupillary-block glaucoma after uneventful cataract surgery treated with intracameral tissue plasminogen activator: a case report[J/OL]. BMC Ophthalmol, 2012, 12: 3[2021-04-20]. https://pubmed.ncbi.nlm.nih.gov/22433746/. DOI: 10.1186/1471-2415-12-3.
81.	Chen YX, Zhang YQ, Chen CZ, et al. Chinese guideline on the management of polypoidal choroidal vasculopathy (2022)[J]. Chin Med Sci J, 2023, 38(2): 77-93. DOI: 10.24920/004213.

1. Feske SK. Ischemic Stroke[J]. Am J Med, 2021, 134(12): 1457-1464. DOI: 10.1016/j.amjmed.2021.07.027.
2. Warach SJ, Dula AN, Milling TJ Jr. Tenecteplase thrombolysis for acute ischemic stroke[J]. Stroke, 2020, 51(11): 3440-3451. DOI: 10.1161/STROKEAHA.120.029749.
3. Levin EG, Santell L. Santell, stimulation and desensitization of tissue plasminogen activator release from human endothelial cells[J]. J Biol Chem, 1988, 263(19): 9360-9365. DOI: 10.1016/S0021-9258(19)76549-1.
4. Geppert A, Graf S, Beckmann R, et al. Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease[J]. Arterioscler Thromb Vasc Biol, 1998, 18(10): 1634-1642. DOI: 10.1161/01.atv.18.10.1634.
5. Levin EG, Marotti KR, Santell L. Protein kinase C and the stimulation of tissue plasminogen activator release from human endothelial cells. Dependence on the elevation of messenger RNA[J]. J Biol Chem, 1989, 264(27): 16030-16036. DOI: 10.1016/S0021-9258(18)71583-4.
6. Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans[J]. Arterioscler Thromb Vasc Biol, 2005, 25(12): 2470-2479. DOI: 10.1161/01.ATV.0000189309.05924.88.
7. Bellien J, Iacob M, Richard V, et al. Evidence for wall shear stress-dependent t-PA release in human conduit arteries: role of endothelial factors and impact of high blood pressure[J]. Hypertens Res, 2021, 44(3): 310-317. DOI: 10.1038/s41440-020-00554-5.
8. Rijken DC. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects[J]. Baillieres Clin Haematol, 1995, 8(2): 291-312. DOI: 10.1016/s0950-3536(05)80269-0.
9. 何香莲. 增殖性糖尿病视网膜病变血浆和眼内组织VEGF与t-PA及PAI的表达及其相关性研究[D]. 银川: 宁夏医科大学, 2014.He XL. Expression and correlation of VEGF, t-PA and PAI in plasma and intraocular tissue of proliferative diabetic retinopathy [D]. Yinchuan: Ningxia Medical University, 2014.
10. Parmer RJ, Gong Y, Yoo SH, et al. Neuroendocrine targeting of tissue plasminogen activator (t-PA)[J/OL]. J Neurol Disord Stroke, 2020, 7(1): 1153[2020-02-12]. https://pubmed.ncbi.nlm.nih.gov/32549050/.
11. 郑斯莉, 缪朝玉. 组织型纤溶酶原激活剂治疗急性缺血性脑卒中的作用机制及临床应用[J]. 中国药理学与毒理学杂志, 2018, 32(8): 595-606. DOI: 10.3867/j.issn.1000-3002.2018.08.002.Zheng SL, Miao CY. Mechanism and clinical application of tissue-type plasminogen activator in treatment of acute ischemic stroke[J]. Chin J Pharmacol Toxicol, 2018, 32(8): 595-606. DOI: 10.3867/j.issn.1000-3002.2018.08.002.
12. Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review[J]. JAMA, 2022, 327(7): 662-675. DOI: 10.1001/jama.2022.0358.
13. Hilkens NA, Casolla B, Leung TW, et al. Stroke[J]. Lancet, 2024, 403(10446): 2820-2836. DOI: 10.1016/s0140-6736(24)00642-1.
14. Babu N, Kumar J, Kohli P, et al. Perfluoro-n-octane-assisted mega Weiss-ring technique for posterior vitreous detachment induction in retinal detachment[J]. Indian J Ophthalmol, 2019, 67(9): 1463-1465. DOI: 10.4103/ijo.IJO_2068_18.
15. Shiraki A, Shiraki N, Sakimoto S, et al. Intraoperative challenges and management of fibrovascular membrane with tractional retinoschisis in proliferative diabetic retinopathy[J]. BMC Ophthalmol, 2024, 24(1): 299. DOI: 10.1186/s12886-024-03555-x.
16. Hsu AY, Chen SN. Ultrawide-field optical coherence tomography in transvitreal and subretinal fibrinoid syndrome: a case report[J]. Case Rep Ophthalmol, 2023, 14(1): 147-152. DOI: 10.1159/000529912.
17. Tandias R, Lemire CA, Palvadi K, et al. Posterior vitreous detachment status as a predictive factor for outcomes of vitrectomy for diabetic vitreous hemorrhage[J]. Retina, 2022, 42(6). DOI: 10.1097/IAE.0000000000003453.
18. Bu SC, Kuijer R, Van Der Worp RJ, et al. The ultrastructural localization of type II, IV, and VI collagens at the vitreoretinal interface[J/OL]. PLoS One, 2015, 10(7): e0134325[2015-07-31]. https://pubmed.ncbi.nlm.nih.gov/26230410/. DOI: 10.1371/journal.pone.0134325.
19. Phillips JD, Hwang ES, Morgan DJ, et al. Structure and mechanics of the vitreoretinal interface[J/OL]. J Mech Behav Biomed Mater, 2022, 134: 105399[2022-08-05]. https://pubmed.ncbi.nlm.nih.gov/35963021/. DOI: 10.1016/j.jmbbm.2022.105399.
20. Lee YS, Wang NK, Chen YP, et al. Plasmin enzyme-assisted vitrectomy in pediatric patients with vitreoretinal diseases[J]. Ophthalmic Res, 2016, 56(4): 193-201. DOI: 10.1159/000447406.
21. Maleki A, Tohidi-Zand SR, Amirizadeh N, et al. Intravitreal autologous plasmin prepared by urokinase for vitreolysis: a pilot study[J]. Eur J Ophthalmol, 2016, 26(1): 67-70. DOI: 10.5301/ejo.5000628.
22. Grinton M, Steel DH. Cochrane corner: ocriplasmin-why isn't it being used more?[J]. Eye (Lond), 2019, 33(8): 1195-1197. DOI: 10.1038/s41433-019-0407-1.
23. Aras C, Senturk F, Koytak A, et al. In vivo generated autologous plasmin assisted vitrectomy in young patients[J]. Int J Retina Vitreous, 2022, 8(1): 36. DOI: 10.1186/s40942-022-00391-3.
24. 冯斐, 赵培泉. 外伤性出血性视网膜脱离的手术疗效分析[J]. 眼外伤职业眼病杂志, 2007, 29(5): 358-360. DOI: 10.3760/cma.j.issn.2095-1477.2007.05.014.Feng F, Zhao PQ. Clinical effect of hemorrhagic retinal detachment due to trauma[J]. Chin J Ocul Traum Occupat Eye Dis, 2007, 29(5): 358-360. DOI: 10.3760/cma.j.issn.2095-1477.2007.05.014.
25. Le Mer Y, Korobelnik JF, Morel C, et al. TPA-assisted vitrectomy for proliferative diabetic retinopathy: results of a double-masked, multicenter trial[J]. Retina, 1999, 19(5): 378-382. DOI: 10.1097/00006982-199909000-00002.
26. Hesse L, Kroll P. TPA-assisted vitrectomy for proliferative diabetic retinopathy[J]. Retina, 2000, 20(3): 317-318. DOI: 10.1097/00006982-200003000-00021.
27. Hesse L, Chofflet J, Kroll P. Tissue plasminogen activator as a biochemical adjuvant in vitrectomy for proliferative diabetic vitreoretinopathy[J]. Ger J Ophthalmol, 1995, 4(6): 323-327.
28. Chuang CC, Chen SN. Induction of posterior vitreous detachment in pediatric vitrectomy by preoperative intravitreal injection of tissue plasminogen activator[J]. J Pediatr Ophthalmol Strabismus, 2016, 53(2): 113-118. DOI: 10.3928/01913913-20160209-01.
29. Aoki R, Hatano M, Higashijima F, et al. Intravitreal tissue plasminogen activator injection for treatment-resistant diabetic macular edema of the vitrectomized eye[J]. Case Rep Ophthalmol, 2021, 12(3): 841-847. DOI: 10.1159/000518289.
30. Liu RZ, Hu YJ, Wang TF, et al. A novel recombinant human microplasminogen induced complete posterior vitreous detachment without morphological change of retina in juvenile rabbits[J/OL]. Exp Eye Res, 2023, 230: 109465[2023-04-06]. https://pubmed.ncbi.nlm.nih.gov/37030582/. DOI: 10.1016/j.exer.2023.109465.
31. Ghasemi Falavarjani K, Anvari P, Dehghan Niri M, et al. The effect of intravitreal recombinant tissue plasminogen activator injection on diabetic tractional fibrovascular membranes: Proposed criteria using optical coherence tomography[J]. Eur J Ophthalmol, 2021, 32(1): 424-428. DOI: 10.1177/1120672121998224.
32. Raczyńska D, Lipowski P, Zorena K, et al. Enzymatic vitreolysis with recombinant tissue plasminogen activator for vitreomacular traction[J]. Drug Des Devel Ther, 2015, 9: 6259-6268. DOI: 10.2147/dddt.S88361.
33. Aras C, Senturk F, Erdur SK, et al. Invivo generated autologous plasmin enzyme assisted vitrectomy, partial circumferential-oral retinotomy, silicone oil injection in patients with chronic retinal detachment without posterior vitreous detachment[J]. Graefe's Arch Clin Exp Ophthalmol, 2024, 262(10): 3109-3116. DOI: 10.1007/s00417-024-06466-1.
34. Casini G, Loiudice P, Menchini M, et al. Traumatic submacular hemorrhage: available treatment options and synthesis of the literature[J/OL]. Int J Retina Vitreous, 2019, 5: 48[2019-12-11]. https://pubmed.ncbi.nlm.nih.gov/31890278/. DOI: 10.1186/s40942-019-0200-0.
35. Hattenbach LO, Grisanti S, Feltgen N, et al. Management of submacular hemorrhage : what, when, how?[J]. Ophthalmologe, 2020, 117(9): 848-857. DOI: 10.1007/s00347-020-01192-5.
36. Chang W, Garg SJ, Maturi R, et al. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration[J]. Am J Ophthalmol, 2014, 157(6): 1250-1257. DOI: 10.1016/j.ajo.2014.02.007.
37. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits[J]. Am J Ophthalmol, 1982, 94(6): 762-773. DOI: 10.1016/0002-9394(82)90301-4.
38. Imam MU, Zhang S, Ma J, et al. Antioxidants mediate both iron homeostasis and oxidative stress[J/OL]. Nutrients, 2017, 9(7): 671[2017-06-28]. https://pubmed.ncbi.nlm.nih.gov/28657578/. DOI: 10.3390/nu9070671.
39. Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage[J]. Surv Ophthalmol, 1997, 42(3): 195-213. DOI: 10.1016/s0039-6257(97)00089-1.
40. Gok M, Karabaş VL, Aslan MS, et al. Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degeneration[J]. Indian J Ophthalmol, 2017, 65(6): 482-487. DOI: 10.4103/ijo.IJO_129_16.
41. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage[J]. Am J Ophthalmol, 1994, 118(5): 559-568. DOI: 10.1016/S0002-9394(14)76571-7.
42. Rickmann A, Paez LR, Della Volpe Waizel M, et al. Functional and structural outcome after vitrectomy combined with subretinal rtPA Injection with or without additional intravitreal Bevacizumab injection for submacular hemorrhages[J/OL]. PLoS One, 2021, 16(4): e0250587[2021-04-30]. https://pubmed.ncbi.nlm.nih.gov/33930041/. DOI: 10.1371/journal.pone.0250587.
43. Tiosano A, Gal-Or O, Fradkin M, et al. Visual acuity outcome in patients with subretinal hemorrhage - office procedure vs. surgical treatment[J]. Eur J Ophthalmol, 2022, 33(1): 506-513. DOI: 10.1177/11206721221098208.
44. 薛晓阳, 刘勃实, 李筱荣. 玻璃体切割术联合视网膜下注射组织型纤溶酶原激活剂对黄斑下出血的疗效观察[J]. 中华实验眼科杂志, 2024, 42(5): 448-452. DOI: 10.3760/cma.j.cn115989-20231012-00125.Xue XY, Liu BS, Li XR. Efficacy of vitrectomy combined with subretinal injection of tissue plasminogen activator on macular hemorrhage[J]. Chin J Exp Ophthalmol, 2024, 42(5): 448-452. DOI: 10.3760/cma.j.cn115989-20231012-00125.
45. Wu TT, Kung YH, Hong MC. Vitreous hemorrhage complicating intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage[J]. Retina, 2011, 31(10): 2071-2077. DOI: 10.1097/IAE.0b013e31822528c8.
46. Kitagawa Y, Shimada H, Mori R, et al. One-year outcome of intravitreal tissue plasminogen activator, ranibizumab, and gas injections for submacular hemorrhage in polypoidal choroidal vasculopathy[J/OL]. J Clin Med, 2022, 11(8): 2175[2022-04-13]. https://pubmed.ncbi.nlm.nih.gov/35456268/. DOI: 10.3390/jcm11082175.
47. Pierre M, Mainguy A, Chatziralli I, et al. Macular hemorrhage due to age-related macular degeneration or retinal arterial macroaneurysm: predictive factors of surgical outcome[J/OL]. J Clin Med, 2021, 10(24): 5787[2021-12-10]. https://pubmed.ncbi.nlm.nih.gov/34945083/. DOI: 10.3390/jcm10245787.
48. Stanescu-Segall D, Balta F, Jackson TL. Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature[J]. Surv Ophthalmol, 2016, 61(1): 18-32. DOI: 10.1016/j.survophthal.2015.04.004.
49. Guthoff R, Guthoff T, Meigen T, et al. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration[J]. Retina, 2011, 31(1): 36-40. DOI: 10.1097/IAE.0b013e3181e37884.
50. Ogata M, Oh H, Nakata A, et al. Displacement of submacular hemorrhage secondary to age-related macular degeneration with subretinal injection of air and tissue plasminogen activator[J/OL]. Sci Rep, 2022, 12(1): 22139[2022-12-22]. https://pubmed.ncbi.nlm.nih.gov/36550175/. DOI: 10.1038/s41598-022-26289-6.
51. Avcı R, Mavi Yıldız A, Çınar E, et al. Subretinal coapplication of tissue plasminogen activator and bevacizumab with concurrent pneumatic displacement for submacular hemorrhages secondary to neovascular age-related macular degeneration[J]. Turk J Ophthalmol, 2021, 51(1): 38-44. DOI: 10.4274/tjo.galenos.2020.72540.
52. Iglicki M, Khoury M, Melamud JI, et al. Naïve subretinal haemorrhage due to neovascular age-related macular degeneration. pneumatic displacement, subretinal air, and tissue plasminogen activator: subretinal vs intravitreal aflibercept-the native study[J]. Eye (Lond), 2023, 37(8): 1659-1664. DOI: 10.1038/s41433-022-02222-z.
53. Ong J, Zarnegar A, Corradetti G, et al. Advances in optical coherence tomography imaging technology and techniques for choroidal and retinal disorders[J/OL]. J Clin Med, 2022, 11(17): 5139[2022-08-31]. https://pubmed.ncbi.nlm.nih.gov/36079077/. DOI: 10.3390/jcm11175139.
54. Zhao X, Zhao Q, Wang E, et al. Three-dimensional heads-up system assisted pars plana vitrectomy and subretinal recombinant tissue plasminogen activator injection for submacular hemorrhage[J]. Eye Vis (Lond), 2023, 10(1): 8. DOI: 10.1186/s40662-023-00326-5.
55. Barzelay A, Daniels A, Cohen GY, et al. Pneumatic displacement with intravitreal tPA injection versus vitrectomy with sub retinal tPA injection in small and medium sub macular hemorrhages- a multicenter comparative study[J]. BMC Ophthalmol, 2024, 24(1): 218. DOI: 10.1186/s12886-024-03468-9.
56. Ali Said Y, Dewilde E, Stalmans P. Visual outcome after vitrectomy with subretinal tpa injection to treat submacular hemorrhage secondary to age-related macular degeneration or macroaneurysm[J/OL]. J Ophthalmol, 2021, 2021: 3160963[2021-12-30]. https://pubmed.ncbi.nlm.nih.gov/35003789/. DOI: 10.1155/2021/3160963.
57. Mehta N, Marco RD, Goldhardt R, et al. Central retinal artery occlusion: acute management and treatment[J]. Curr Ophthalmol Rep, 2017, 5(2): 149-159. DOI: 10.1007/s40135-017-0135-2.
58. Yao Y, Song Q, Zhang J, et al. Retina-brain homology: the correlation between ophthalmic or retinal artery occlusion and ischemic stroke[J]. Eye Brain, 2024, 16: 25-38. DOI: 10.2147/EB.S454977.
59. Bénard-Séguin É, Nahab F, Pendley AM, et al. Eye stroke protocol in in the emergency department[J/OL]. J Stroke Cerebrovasc Dis, 2024, 33(9): 107895[2024-07-28]. https://pubmed.ncbi.nlm.nih.gov/39079617/. DOI: 10.1016/j.jstrokecerebrovasdis.2024.107895.
60. Venkatesh R, Joshi A, Maltsev D, et al. Update on central retinal artery occlusion[J]. Indian J Ophthalmol, 2024, 72(7): 945-955. DOI: 10.4103/ijo.Ijo_2826_23.
61. Schorr EM, Rossi KC, Stein LK, et al. Characteristics and outcomes of retinal artery occlusion: nationally representative data[J]. Stroke, 2020, 51(3): 800-807. DOI: 10.1161/strokeaha.119.027034.
62. Youn TS, Lavin P, Patrylo M, et al. Current treatment of central retinal artery occlusion: a national survey[J]. J Neurol, 2018, 265(2): 330-335. DOI: 10.1007/s00415-017-8702-x.
63. Mac Grory B, Schrag M, Biousse V, et al. Management of central retinal artery occlusion: a scientific statement from the american heart association[J/OL]. Stroke, 2021, 52(6): e282-e294[2021-04-08]. https://pubmed.ncbi.nlm.nih.gov/33677974/. DOI: 10.1161/STR.0000000000000366.
64. Kattah JC, Wang DZ, Reddy C. Intravenous recombinant tissue-type plasminogen activator thrombolysis in treatment of central retinal artery occlusion[J]. Arch Ophthalmol, 2002, 120(9): 1234-1236. DOI: 10.1001/archopht.120.9.1234.
65. Schrag M, Youn T, Schindler J, et al. Intravenous fibrinolytic therapy in central retinal artery occlusion: a patient-level meta-analysis[J]. JAMA Neurol, 2015, 72(10): 1148-1154. DOI: 10.1001/jamaneurol.2015.1578.
66. Liu Y, Cao S, Zhao Y, et al. Network meta-analysis of different thrombolytic strategies for the treatment of central retinal artery occlusion[J]. Semin Ophthalmol, 2024, 39(2): 129-138. DOI: 10.1080/08820538.2023.2249539.
67. Shahjouei S, Bavarsad Shahripour R, Dumitrascu OM. Thrombolysis for central retinal artery occlusion: an individual participant-level meta-analysis[J]. Int J Stroke, 2024, 19(1): 29-39. DOI: 10.1177/17474930231189352.
68. Raber FP, Gmeiner F, Dreyhaupt J, et al. Thrombolysis in central retinal artery occlusion: a retrospective observational study[J]. J Neurol, 2022, 270: 891-897. DOI: 10.1007/s00415-022-11439-7.
69. Kožner P, Eichenmann L, Ceska Burdova M, et al. Long-term outcomes of intravenous fibrinolysis in central retinal artery occlusion[J/OL]. Sci Rep, 2023, 13(1): 20505[2023-11-22]. https://pubmed.ncbi.nlm.nih.gov/37993533/. DOI: 10.1038/s41598-023-47987-9.
70. Lin J C, Song S, Ng SM, et al. Interventions for acute non-arteritic central retinal artery occlusion[J/OL]. Cochrane Database Syst Rev, 2023, 1(1): Cd001989[2023-01-30]. https://pubmed.ncbi.nlm.nih.gov/36715340/. DOI: 10.1002/14651858.CD001989.pub3.
71. Tiwari V, Bagga SSJ, Prasad R, et al. A review of current literature on central retinal artery occlusion: its pathogenesis, clinical management, and treatment[J/OL]. Cureus, 2024, 16(3): e55814[2024-03-08]. https://pubmed.ncbi.nlm.nih.gov/38590501/. DOI: 10.7759/cureus.55814.
72. Smith MJ, Benson MD, Tennant M, et al. Central retinal artery occlusion: a retrospective study of disease presentation, treatment, and outcomes[J]. Can J Ophthalmol, 2023, 58(4): 318-323. DOI: 10.1016/j.jcjo.2022.02.015.
73. Cantor LB, Katz LJ, Spaeth GL. Complications of surgery in glaucoma. suprachoroidal expulsive hemorrhage in glaucoma patients undergoing intraocular surgery[J]. Ophthalmology, 1985, 92(9): 1266-1270. DOI: 10.1016/s0161-6420(85)33872-1.
74. Taylor DM. Expulsive hemorrhage[J]. Am J Ophthalmol, 1974, 78(6): 961-966. DOI: 10.1016/0002-9394(74)90809-5.
75. Stein JD, Zacks DN, Grossman D, et al. Adverse events after pars plana vitrectomy among medicare beneficiaries[J]. Arch Ophthalmol, 2009, 127(12): 1656-1663. DOI: 10.1001/archophthalmol.2009.300.
76. 黄易, 胡海坚, 张旭. 暴发性脉络膜上腔出血的研究进展[J]. 国际眼科纵览, 2022, 46(6): 522-527. DOI: 10.3760/cma.j.issn.1673-5803.2022.06.009.Huang Y, Hu HJ, Zhang X. Advance in the study of expulsive suprachoroidal hemorrhage[J]. Int Rev Ophthalmol, 2022, 46(6): 522-527. DOI: 10.3760/cma.j.issn.1673-5803.2022.06.009.
77. Kunjukunju N, Gonzales CR, Rodden WS. Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage[J]. Clin Ophthalmol, 2011, 5: 155-157. DOI: 10.2147/opth.S16134.
78. Fei P, Jin HY, Zhang Q, et al. Tissue plasminogen activator-assisted vitrectomy in the early treatment of acute massive suprachoroidal hemorrhage complicating cataract surgery[J]. Int J Ophthalmol, 2018, 11(1): 170-171. DOI: 10.18240/ijo.2018.01.27.
79. Osaadon P, Belfair N, Lavy I, et al. Intracameral r-tPA for the management of severe fibrinous reactions in tass after cataract surgery[J]. Eur J Ophthalmol, 2022, 32(1): 200-204. DOI: 10.1177/11206721211002064.
80. Yoshino H, Seki M, Ueda J, et al. Fibrin membrane pupillary-block glaucoma after uneventful cataract surgery treated with intracameral tissue plasminogen activator: a case report[J/OL]. BMC Ophthalmol, 2012, 12: 3[2021-04-20]. https://pubmed.ncbi.nlm.nih.gov/22433746/. DOI: 10.1186/1471-2415-12-3.
81. Chen YX, Zhang YQ, Chen CZ, et al. Chinese guideline on the management of polypoidal choroidal vasculopathy (2022)[J]. Chin Med Sci J, 2023, 38(2): 77-93. DOI: 10.24920/004213.

Chinese Journal of Ocular Fundus Diseases

Latest ArticlesResearch progress of tissue plasminogen activator in ophthalmic treatment

Abstract Full text Figures/Tables Video References Cited by

Format

Content